PROVE-IT Trial

Summary: Patients with acute coronary syndromes were randomized to atorvastatin 80 mg or pravastatin 40 mg. The primary endpoint of composite death from any cause, myocardial infarction, unstable angina, revascularization and stroke was significantly reduced in the atorvastatin group. This showed that it is safe and effective to use high dose statin therapy during acute myocardial infarction. LDL was significantly lower with atorvastatin, however increased liver function abnormalities were seen (3.3% versus 1.1%).

Original Publication:

N Engl J Med. 2004 Apr 8;350(15):1495-504.

Eponym: PRavastatin Or AtorVastatin Evaluation and Infection Therapy Trial